AlphAIalphai — Financial news for AI agents
BenzingaNOV 122 min read$CRMD

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations - Cormedix (NASDAQ:CRMD)

CorMedix Inc. ( NASDAQ:CRMD ) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents. Sales reached $104.27 million, a jump from $11.5 million a year ago, beating the consensus of $86.02 million.

Original reporting
Benzinga · Vandana Singh
Published Nov 12, 2025, 4:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 12, 2025, 5:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations - Cormedix (NASDAQ:CRMD) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$CRMDBullishMed
01

Why it matters

The strong quarterly results suggest sustained demand, which could lead to further stock appreciation.

02

Market read

The news is highly relevant for investors interested in biotech and healthcare sectors, especially those focusing on dialysis-related companies.

03

What to watch

Potential supply chain issues or regulatory hurdles could temper the stock's upside.

Timing: Immediate, as earnings are recent and market reaction is ongoing.

Background

CorMedix reported a substantial increase in earnings and sales, driven by higher demand for DefenCath in dialysis treatments.

Company-level read

Ticker impact

$CRMDBullishHigh confidence
Context

The news highlights a significant quarterly earnings beat and increased sales for CorMedix Inc., indicating strong company performance and positive market sentiment.

Expected impact

Moderate upward movement in stock price over the short term.

Evidence & confidence

The earnings beat and revenue growth significantly exceed analyst expectations, indicating strong operational performance and market acceptance.

Market effects

Sector

Positive for the biotech and medical device sectors, especially companies involved in dialysis and related therapies.

Regional

Potential uplift in US healthcare sector indices.

Global

Limited, as the news pertains primarily to a US-based company with specific product demand.

Counterpoint

What could challenge this read

The rally may be short-lived if upcoming earnings guidance is conservative or if market conditions change unexpectedly.

Key entities

  • Company
    CorMedix Inc.

    A biotech firm specializing in medical devices for dialysis.

  • Product
    DefenCath

    A medical device used in dialysis procedures.

Read at source← All news

Related articles

AUG 14
$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

yahoo.com6 min
AUG 13
$CRMDMedAI 8/10

CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.

finanznachrichten.de6 min
AUG 13
$CRMDHigh

CorMedix Inc. (CRMD): Results of Operations and Financial Condition

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 crmd_q22026earningspr.htm EX-99.1 Document Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 m

SEC EDGAR 8-K7 min
AUG 14
$UWMCMed

UWM sued for allegedly misleading investors on hedge strategy

Shareholder Doug Bond filed a class action against UWM Holdings in Michigan federal court, alleging securities fraud over disclosures about UWM’s interest rate derivatives hedge tied to its Two Harbors acquisition. The suit covers purchases from March 9 to Aug. 5, citing a $603.2 million derivatives loss and a $2.05 billion Oaktree cash infusion after a March revenue projection.

nationalmortgagenews.com4 min
AUG 14
$BAMedAI 8/10

Pentagon inks deals with Boeing, RTX to boost production of SM-3 components

The Pentagon signed seven-year framework agreements with Boeing and RTX to expand production of Standard Missile-3 components for SM-3 Block IB and Block IIA, including avionics and ejector assemblies Boeing supplies to Raytheon. The deals aim to stabilize supply chains and expand munitions output. Separately, the Missile Defense Agency awarded Raytheon a $745 million contract for Block IIA interceptors.

militarytimes.com5 min